Germany: CSL’s Andembry HTA Submission Offers Critical Indirect Comparison Lessons

 
• By Francesca Bruce
  
German HTA says CSL Behring's Andembry offers aditional benefit for hereditary angioedema compared to Biocryst’s Orladeyo. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Pink Sheet